Cocktail Therapy Combining SGLT2 Inhibitor, Entresto, and Adipose-Derived Mesenchymal Stem Cells Prevents Abdominal Aortic Aneurysmal Complication Syndrome in Rodents. (PubMed, Acta Cardiol Sin) - Sep 25, 2026 - "This study investigated whether triple combination therapy [dapagliflozin (DAPA) + sacubitril/valsartan (Entresto) + adipose-derived mesenchymal stem cells (ADMSCs)] offered additional benefits on preventing complication syndrome [defined as abdominal aortic aneurysm (AAA) dilatation, muscle layer destruction and inflammation] in rodents with AAA. The protein expressions of inflammation (tumor necrosis factor-alpha/interleukin (IL)-1 beta/IL-6/MMP2/MMP9)/fibrosis (transforming growth factor-beta/mothers against decapentaplegic homolog 3) markers displayed an identical pattern, whereas the protein expressions of tissue inhibitors of metalloproteinases (tissue inhibitor of metalloproteinases-1/tissue inhibitor of metalloproteinases-2) and apoptosis (cleaved-Caspase3/cleaved-poly(ADP-ribose) polymerase) displayed an opposite pattern of AAA diameter among the groups (all p < 0.0001). The results of the present study support that triple therapy with DAPA + Entresto..."
Journal • Preclinical • Cardiovascular • Immunology • Inflammation • Oncology • CASP3 • CD4 • IL6 • MMP2 • MMP9 • SMAD4 • TIMP1 • TNFA
|
|
Han-Tan Chai; Hon-Kan Yip; Jiunn-Jye Sheu; Pei-Hsun Sung; Sheung-Fat Ko; Yi-Ling Chen
|